OR WAIT null SECS
NGS abbreviates drug discovery timelines.
There is a great need for sensitive, precise, and easily accessible analytical detection techniques for protein sequencing.
Developing cell-based potency assays for cell therapies requires meticulous coordination.
January 16, 2024
Webinar Date/Time: Wed, Feb 28, 2024 11:00 AM EST
January 11, 2024
Webinar Date/Time: Thu, Feb 8, 2024 11:00 AM EST
January 04, 2024
Roche will acquire select parts of the LumiraDx group related to that company’s point-of-care technology, which integrates multiple tests on a single instrument.
January 01, 2024
December 28, 2023
Tome Bioscience is facilitating the transition in biology from the editing phase to the cut-and-paste phase.
December 13, 2023
A single protein or gene expression product can exist in multiple proteoforms due to alternative splicing, point mutations, post translational modifications and endogenous proteolysis.
December 08, 2023
This collaboration will combine BigHat Biosciences’ AI/ML-guided Milliner platform with AbbVie's expertise in oncology and neuroscience to develop next-generation antibodies.
MilliporeSigma’s new platform combines generative AI, machine learning, and computer-aided drug-design aimed at increasing the success rate of new drugs and therapies.
December 01, 2023
Sufficient stability studies show a drug product meets regulatory requirements, therefore ensuring the drug reaches the patients who rely on it.
November 29, 2023
TAU Systems plans to establish TAU Labs, a new next-generation, laser-driven plasma accelerator laboratory, in Carlsbad, Calif.